Thu, Mar 6, 10:05 PM (51 days ago)
This 10-K/A amendment for Day One Biopharmaceuticals, Inc. (DAWN) primarily addresses corrections to previously filed consent and audit reports, with no changes to financial data. For the fiscal year ended December 31, 2024, the company reported total revenues of $131.2 million, driven by product revenue of $57.2 million and license revenue of $73.9 million. Operating expenses totaled $348.4 million, leading to a net loss of $95.5 million, or $1.02 per share. Research and development costs surged to $227.7 million, reflecting ongoing clinical trials and product development. The company maintained a strong cash position with $125 million in cash and equivalents and $407 million in short-term investments. The financial condition remains robust, with total assets of $582.8 million against liabilities of $80 million. Significant risks include reliance on key product approvals and third-party manufacturers. Future outlook hinges on commercialization success of OJEMDA and further developments under licensing agreements, including potential milestone payments totaling $330 million from Ipsen. The amendment does not restate prior financials but ensures compliance with SEC regulations.